AccuMed and Biokit in joint venture:
This article was originally published in Clinica
Executive Summary
AccuMed International (US) and Biokit (Spain) have signed a joint venture agreement to develop a low-cost, automatic Kirby Bauer reader. Biokit will license software to AccuMed as part of a worldwide technology agreement. The deal "will result in the earlier development of our unique proprietary system for the $250 million market", says Peter Gombrich, CEO of AccuMed. Kirby Bauer systems test microbiology samples to identify the most suitable type and concentration of antibiotics. Terms of the deal were not disclosed.